Thought Leaders Target Adoption of Goal-Directed Haemodynamic Therapy

The University of Pennsylvania (Upenn) in conjunction with Evidence Based Perioperative Medicine (EBPOM) and UK Department for International Trade (DIT) has hosted the third annual “Quality Improvement Leadership Forum” with the goal of sharing experiences from the implementation of clinical initiatives. The forum was a collaboration of US and UK thought leaders from top teaching hospitals. The focus this year was on dissemination and implementation on the road to adoption of initiatives that improve patient outcomes.

One area of discussion was hemodynamic monitoring, centering on a presentation by UCL, London’s Professor Monty Mythen on the recently published (BJA) FEDORA study. Specifically the focus was on Goal-Directed Haemodynamic (rather than just Fluid) Therapy (GDHT vs GDFT). This combines managed delivery of fluids to maintain stroke volume, with inotropes and vasopressors to maintain target levels of mean arterial pressure and cardiac index (Deltex Medical’s Doppler-based ODM+ system is unique in its ability to guide vasoactive agents and inotropes along with fluid for complete haemodynamic therapy).

Not just for High Risk Patients

The FEDORA 420 patient randomised, controlled, multi centre trial yielded statistically significant data showing a 75% reduction of postoperative complications in patients considered to be at low-moderate risk, undergoing major elective surgery. Among the serious complications avoided were Acute Kidney Injury and Surgical Site Infection. Overall results showed a reduced length of hospital stay.

The group concluded that monitoring hemodynamics should be standard of care pre, during and post surgery. This then lead to discussion about how to deliver sustainable adoption of GDHT as a clinically supported best practice. The consensus was that horizontal implementation provides the best likelihood of success. This means introducing GDHT across the service as opposed to one surgical specialty at a time.

The forum agreed to generate two white papers. One will be a quick survey of opioid use, understanding how each hospital is addressing this ongoing crisis.  The second paper will be about dissemination and implementation with the goal to come up with best practice on gaining adoption of new protocols and therapies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Deltex Medical Group Plc

    More articles like this

    Deltex Medical Group Plc

    Deltex Medical Group plc in a strong financial position

    Nigel Keen, Chairman of Deltex Medical, commented: “The successful £2,050,000 fund raising in February 2018 has put the Group in a stronger financial position – allowing us to improve our business structure. “We made a number

    Deltex Medical Group Plc

    INTERVIEW: Deltex Medical Group New CEO Andy Mears

    Deltex Medical Group Plc (LON:DEMG) New CEO Andy Mears talks to DirectorsTalk about his new position. Andy talks about his background, how he thinks Deltex is positioned, his plans for the next 12 months and the

    Deltex Medical Group Plc

    Deltex Medical Group plc New Chief Executive

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, announced today that Ewan Phillips has resigned as Chief Executive and as a Director of the Company with immediate effect. Mr. Phillips recently approached Deltex’s

    Deltex Medical Group Plc

    Another Successful Learning Event Sponsored by Deltex

    May 28th saw Deltex Medical Group supporting Current Initiatives, Research and the Role of Haemodynamic Monitoring at London’s Montague Hotel. Held under the auspices of the EBPOM organisation (Evidence Based PeriOperative Medicine), the congress saw keynote presentations from

    Deltex Medical Group Plc

    CEO Q&A with Ewan Phillips at Deltex Medical Group plc (LON:DEMG)

    Deltex Medical Group’s Ewan Phillips discusses their full year results, what’s been happening operationally, their strategy for the next 12 months and what investors should look forward to in the near future in this exclusive interview with DirectorsTalk

    Deltex Medical Group Plc

    Deltex Medical Group PLC Investor Event

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), today announced that it will be hosting an investor event on 22 May 2018 following the publication of its full year results for

    Deltex Medical Group Plc

    Deltex Sponsoring Evidence-Based Clinical Event

    Deltex Medical will be supporting a forthcoming congress in London on May 28th. Current Initiatives, Research and the Role of Hemodynamic Monitoring is free to attend for clinicians and healthcare providers who are interested in the principles and

    Deltex Medical Group Plc

    Critical caring

    It takes a plethora of products and people to provide patients premium protection. Changing payment models, the digitization of healthcare and the need to deliver higher quality care at a lower cost are driving significant change